<DOC>
	<DOCNO>NCT02975700</DOCNO>
	<brief_summary>The purpose Phase I/II study evaluate safety , pharmacokinetics , preliminary efficacy investigational drug PLX3397 subject unresectable metastatic KIT-mutated melanoma .</brief_summary>
	<brief_title>A Study PLX3397 Patients With Unresectable Metastatic KIT-mutated Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Age ≥ 18 year Unresectable stage III stage IV melanoma histologically confirm treat institution KIT mutation ( ) know resistant PLX3397 Presence measurable lesion Response Evaluation Criteria Solid Tumors Eastern Cooperative Oncology Group ( ECOG ) performance Status ( PS ) 02 Life expectancy ≥ 3 month Adequate organ bone marrow function Women childbearing potential must negative serum pregnancy test Screening must agree use effective form contraception time negative pregnancy test 3 month last dose study drug . Women nonchildbearing potential must postmenopausal ≥ 1 year surgically sterile . Fertile men must agree use effective method birth control study 3 month last dose study drug . Willingness ability provide write informed consent prior studyrelated procedure comply study requirement Prior treatment KIT inhibitor melanoma Presence NRAS BRAF mutation Exposure investigational drug within 28 day unresolved adverse effect previous therapy Symptomatic brain metastasis . Active secondary malignancy unless malignancy expect interfere evaluation safety approve Sponsor Concomitant treatment antineoplastic agent ( hormonal therapy acceptable ) Uncontrolled intercurrent infectious illness Major surgical procedure significant traumatic injury within 14 day initiate study drug anticipation need major surgery study Previous radiotherapy 25 % bone marrow and/or radiation therapy within 28 day prior study entry Inability swallow capsule , refractory nausea vomiting , malabsorption , external biliary shunt , significant bowel resection would preclude adequate absorption Congestive heart failure ( CHF ) New York ( NY ) Heart Association class III IV ; unstable coronary artery disease ( myocardial infarction [ MI ] 6 month prior study entry permit ) ; serious cardiac arrhythmia Baseline QTcF ≥ 450 msec ( male ) ≥ 470 msec ( female ) Screening Active chronic infection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) Known chronic liver disease Women breastfeeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PLX3397</keyword>
	<keyword>Kit-mutant Melanoma</keyword>
</DOC>